Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Imaging of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer
NCT02683083Phase 1Completed
- Sponsor
- Precirix
- Start
- Oct 2016
- Primary completion
- Feb 2018
- Modality
- Nanobodies (VHH)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAM-H2 in breast cancer, sponsored by Precirix. Primary endpoints: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 at 1 day, Biodistribution of [131I]-SGMIB Anti-HER2 VHH1 and 1 more. Started Oct 2016; status: completed.
02
Drugs
CAM-H2
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02683083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02683083.